- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Senior UK-based AstraZeneca employees ‘liked’ LinkedIn posts linking to press releases about Imfinzi combinations and trial results. The PMCPA ruled promotion to…
NHS Health Board HCPs alleged an Ethypharm representative made unannounced visits and shared factually incorrect information about blocked prefilled syringes. Panel ruled…
Complaint alleged a CKD management video indirectly promoted Forxiga via SGLT2 inhibitor references and lacked PI/AE statements. Panel found the content balanced,…
Complaint about a UK speaker’s CLL symposium at EHA 2023 (Frankfurt) where an ALPINE trial slide was not shown live. Panel found…
Theramex’s LinkedIn ‘About Us’ described its solutions as “innovative, effective and safe”. The PMCPA ruled this was misleading and used ‘safe’ without…
PMCPA ruled Jazz’s Epidyolex HCP video misleading for presenting hepatic monitoring/dosing without clearly stating the SmPC contraindication (ALT/AST >3x ULN with bilirubin…
PMCPA ruled Roche breached Clause 9.10 (2016) because a university webpage described Roche only as “Client”, an ambiguous disclosure. The white paper…
A pharmacist complained a launch letter promoted off-label use of Melatonin 1mg/ml Oral Solution. The Panel ruled the letter promoted off-label use,…
A primary care trust chief pharmacist questioned whether a Champix ad in the Health Service Journal could be seen by non-health professionals.…
Roche was ruled in breach after Xenical was effectively supplied via a non-health professional at a private clinic and a proposed £55,000…
A freelance medical writer challenged Ferinject materials used at a renal meeting. The Panel ruled claims about dosing and infusion-time comparisons misleading,…
GSK challenged Pfizer’s Champix detail aid on efficacy comparisons vs NRT, NNT and cost-effectiveness claims, and safety/prescribing information. The Panel ruled no…
Roche challenged two GSK corporate press releases about lapatinib (Tykerb/Tyverb). The Panel found one release misleading on adverse event/risk-benefit balance, but rejected…
Cephalon challenged ProStrakan leavepieces claiming Abstral provided rapid relief from 10 minutes. The Panel found the claim inconsistent with the Abstral SPC,…
A MASTA rep sent an unapproved promotional email about Epaxal without prescribing info. Follow-up “training” pointed staff to an out-of-date Code and…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.